173 related articles for article (PubMed ID: 26707159)
1. Cost-benefits of incorporating levosimendan into cardiac surgery practice: German base case.
Mardiguian S; Kivikko M; Heringlake M; Smare C; Bertranou E; Apajasalo M; Pollesello P
J Med Econ; 2016; 19(5):506-14. PubMed ID: 26707159
[TBL] [Abstract][Full Text] [Related]
2. The costs of treating acute heart failure: an economic analysis of the SURVIVE trial.
de Lissovoy G; Fraeman K; Salon J; Chay Woodward T; Sterz R
J Med Econ; 2008; 11(3):415-29. PubMed ID: 19450096
[TBL] [Abstract][Full Text] [Related]
3. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial.
Cleland JG; Takala A; Apajasalo M; Zethraeus N; Kobelt G
Eur J Heart Fail; 2003 Jan; 5(1):101-8. PubMed ID: 12559222
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of levosimendan in patients with acute heart failure.
Fedele F; D'Ambrosi A; Bruno N; Caira C; Brasolin B; Mancone M
J Cardiovasc Pharmacol; 2011 Oct; 58(4):363-6. PubMed ID: 21697728
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of levosimendan versus dobutamine for the treatment of acute heart failure in Italy.
Lucioni C; D'Ambrosi A; Mazzi S; Pollesello P; Apajasalo M; Fedele F
Adv Ther; 2012 Dec; 29(12):1037-50. PubMed ID: 23233357
[TBL] [Abstract][Full Text] [Related]
6. Hospital costs for treatment of acute heart failure: economic analysis of the REVIVE II study.
de Lissovoy G; Fraeman K; Teerlink JR; Mullahy J; Salon J; Sterz R; Durtschi A; Padley RJ
Eur J Health Econ; 2010 Apr; 11(2):185-93. PubMed ID: 19582491
[TBL] [Abstract][Full Text] [Related]
7. Levosimendan for Hemodynamic Support after Cardiac Surgery.
Landoni G; Lomivorotov VV; Alvaro G; Lobreglio R; Pisano A; Guarracino F; Calabrò MG; Grigoryev EV; Likhvantsev VV; Salgado-Filho MF; Bianchi A; Pasyuga VV; Baiocchi M; Pappalardo F; Monaco F; Boboshko VA; Abubakirov MN; Amantea B; Lembo R; Brazzi L; Verniero L; Bertini P; Scandroglio AM; Bove T; Belletti A; Michienzi MG; Shukevich DL; Zabelina TS; Bellomo R; Zangrillo A;
N Engl J Med; 2017 May; 376(21):2021-2031. PubMed ID: 28320259
[TBL] [Abstract][Full Text] [Related]
8. Levosimendan: new indications and evidence for reduction in perioperative mortality?
Pisano A; Monti G; Landoni G
Curr Opin Anaesthesiol; 2016 Aug; 29(4):454-61. PubMed ID: 27168089
[TBL] [Abstract][Full Text] [Related]
9. The effects of levosimendan in cardiac surgery patients with poor left ventricular function.
De Hert SG; Lorsomradee S; Cromheecke S; Van der Linden PJ
Anesth Analg; 2007 Apr; 104(4):766-73. PubMed ID: 17377079
[TBL] [Abstract][Full Text] [Related]
10. [Cost analysis of the treatment of acute decompensated heart failure. Levosimendan versus dobutamine].
Oliveira MT; Follador W; Martins ML; Canaviera R; Tsuji RL; Scipioni A; Barretto AC
Arq Bras Cardiol; 2005 Jul; 85(1):9-14. PubMed ID: 16041448
[TBL] [Abstract][Full Text] [Related]
11. Perioperative use of levosimendan: best practice in operative settings.
Toller W; Algotsson L; Guarracino F; Hörmann C; Knotzer J; Lehmann A; Rajek A; Salmenperä M; Schirmer U; Tritapepe L; Weis F; Landoni G
J Cardiothorac Vasc Anesth; 2013 Apr; 27(2):361-6. PubMed ID: 22658687
[No Abstract] [Full Text] [Related]
12. [Levosimendan and dobutamine have a similar profile for potential risk for cardiac arrhythmias during 24-hour infusion in patients with acute decompensated heart failure].
Tek M; Cavuşoğlu Y; Demirüstü C; Birdane A; Ünalır A; Görenek B; Göktekin Ö; Ata N
Turk Kardiyol Dern Ars; 2010 Jul; 38(5):334-40. PubMed ID: 21200103
[TBL] [Abstract][Full Text] [Related]
13. A randomized controlled trial of levosimendan to reduce mortality in high-risk cardiac surgery patients (CHEETAH): Rationale and design.
Zangrillo A; Alvaro G; Pisano A; Guarracino F; Lobreglio R; Bradic N; Lembo R; Gianni S; Calabrò MG; Likhvantsev V; Grigoryev E; Buscaglia G; Pala G; Auci E; Amantea B; Monaco F; De Vuono G; Corcione A; Galdieri N; Cariello C; Bove T; Fominskiy E; Auriemma S; Baiocchi M; Bianchi A; Frontini M; Paternoster G; Sangalli F; Wang CY; Zucchetti MC; Biondi-Zoccai G; Gemma M; Lipinski MJ; Lomivorotov VV; Landoni G
Am Heart J; 2016 Jul; 177():66-73. PubMed ID: 27297851
[TBL] [Abstract][Full Text] [Related]
14. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
Follath F
Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
[TBL] [Abstract][Full Text] [Related]
15. Effect of levosimendan on survival and adverse events after cardiac surgery: a meta-analysis.
Harrison RW; Hasselblad V; Mehta RH; Levin R; Harrington RA; Alexander JH
J Cardiothorac Vasc Anesth; 2013 Dec; 27(6):1224-32. PubMed ID: 24050857
[TBL] [Abstract][Full Text] [Related]
16. Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure.
Oner E; Erturk M; Birant A; Kurtar Mansıroglu A; Akturk IF; Karakurt H; Yalcin AA; Uzun F; Somuncu MU; Yildirim A
Cardiol J; 2015; 22(1):87-93. PubMed ID: 24846511
[TBL] [Abstract][Full Text] [Related]
17. Pharmaco-economics of levosimendan in cardiology: a European perspective.
Nieminen MS; Buerke M; Parissis J; Ben-Gal T; Pollesello P; Kivikko M; Karavidas A; Severino P; Comín-Colet J; Wikström G; Fedele F
Int J Cardiol; 2015 Nov; 199():337-41. PubMed ID: 26241640
[TBL] [Abstract][Full Text] [Related]
18. Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery.
Mehta RH; Leimberger JD; van Diepen S; Meza J; Wang A; Jankowich R; Harrison RW; Hay D; Fremes S; Duncan A; Soltesz EG; Luber J; Park S; Argenziano M; Murphy E; Marcel R; Kalavrouziotis D; Nagpal D; Bozinovski J; Toller W; Heringlake M; Goodman SG; Levy JH; Harrington RA; Anstrom KJ; Alexander JH;
N Engl J Med; 2017 May; 376(21):2032-2042. PubMed ID: 28316276
[TBL] [Abstract][Full Text] [Related]
19. Levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery on cardiopulmonary bypass: Rationale and study design of the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CTS) trial.
Mehta RH; Van Diepen S; Meza J; Bokesch P; Leimberger JD; Tourt-Uhlig S; Swartz M; Parrotta J; Jankowich R; Hay D; Harrison RW; Fremes S; Goodman SG; Luber J; Toller W; Heringlake M; Anstrom KJ; Levy JH; Harrington RA; Alexander JH;
Am Heart J; 2016 Dec; 182():62-71. PubMed ID: 27914501
[TBL] [Abstract][Full Text] [Related]
20. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery.
Tritapepe L; De Santis V; Vitale D; Guarracino F; Pellegrini F; Pietropaoli P; Singer M
Br J Anaesth; 2009 Feb; 102(2):198-204. PubMed ID: 19151048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
